Abstract
Epilepsy is an excellent indication for gene therapy due to a significant unmet need, which is the high percentage of patients with symptoms that remain inadequately relieved by the current available treatments. This chapter provides an up-to-date review on the preclinical studies assessing the potential of gene therapy for epilepsy. We also provide here a set of procedures that can be used as a starting point to evaluate potential therapeutic candidates for epilepsy gene therapy. The techniques described here include adeno-associated viral vector production, genomic titering of the vector, stereotaxic neurosurgery for intracerebral vector administration, and the kainic acid seizure model.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hirtz D, Thurman DJ, Gwinn-Hardy K et al (2007) How common are the “common” neurologic disorders? Neurology 68(5):326–337
Cascino GD (2008) When drugs and surgery don’t work. Epilepsia 49(Suppl 9):79–84
Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342(5):314–319
Loscher W, Ebert U, Lehmann H et al (1998) Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra. J Neurosci Res 51(2):196–209
Thompson KW, Suchomelova LM (2004) Transplants of cells engineered to produce GABA suppress spontaneous seizures. Epilepsia 45(1):4–12
Castillo CG, Mendoza-Trejo S, Aguilar MB et al (2008) Intranigral transplants of a GABAergic cell line produce long-term alleviation of established motor seizures. Behav Brain Res 193(1):17–27
Nolte MW, Loscher W, Herden C et al (2008) Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures. Neurobiol Dis 31(3):342–354
Xiao X, McCown TJ, Li J et al (1997) Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 756(1–2):76–83
Brooks-Kayal AR, Shumate MD, Jin H et al (1998) Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med 4(10):1166–1172
Raol YH, Lund IV, Bandyopadhyay S et al (2006) Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 26(44):11342–11346
Shan W, Wu X, Zhang G et al (1997) Effects of antisense oligodeoxynucleotides to NR1 on suppression of seizures and protection of cortical neurons from excitotoxicity in vivo and in vitro. Chin Med J (Engl) 110(8):579–583
Haberman R, Criswell H, Snowdy S et al (2002) Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 6(4):495–500
Kalev-Zylinska ML, Symes W, Young D et al (2009) Knockdown and overexpression of NR1 modulates NMDA receptor function. Mol Cell Neurosci 41(4):383–396
During MJ, Symes CW, Lawlor PA et al (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287(5457):1453–1460
Mazarati AM, Hohmann JG, Bacon A et al (2000) Modulation of hippocampal excitability and seizures by galanin. J Neurosci 20(16):6276–6281
Vezzani A, Hoyer D (1999) Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur J Neurosci 11(11):3767–3776
Vezzani A, Sperk G, Colmers WF (1999) Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 22(1):25–30
Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9(8):1076–1080
Lin EJ, Richichi C, Young D et al (2003) Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 18(7):2087–2092
McCown TJ (2006) Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 14(1):63–68
Richichi C, Lin EJ, Stefanin D et al (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24(12):3051–3059
Noe F, Pool AH, Nissinen J et al (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131(Pt 6):1506–1515
Noe F, Vaghi V, Balducci C et al (2010) Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther 17(5):643–652
Lin EJ, Young D, Baer K et al (2006) Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 47(4):773–780
Foti S, Haberman RP, Samulski RJ et al (2007) Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther 14(21):1534–1536
Woldbye DP, Angehagen M, Gotzsche CR et al (2010) Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 133(9):2778–2788
Gotzsche CR, Nikitidou L, Sorensen AT et al (2012) Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol Dis 45(1):288–296
Olesen MV, Christiansen SH, Gotzsche CR et al (2012) Neuropeptide Y Y1 receptor hippocampal overexpression via viral vectors is associated with modest anxiolytic-like and proconvulsant effects in mice. J Neurosci Res 90(2):498–507
Sorensen AT, Kanter-Schlifke I, Carli M et al (2008) NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus 18(6):564–574
Sorensen AT, Nikitidou L, Ledri M et al (2009) Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol 215(2):328–333
Lin EJ, Lin S, Aljanova A et al (2010) Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice. Eur Neuropsychopharmacol 20(3):164–175
Olesen MV, Christiansen SH, Gotzsche CR et al (2012) Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity. Neuropeptides 46(2):71–79
Tallent MK, Qiu C (2008) Somatostatin: an endogenous antiepileptic. Mol Cell Endocrinol 286(1–2):96–103
Hashimoto T, Obata K (1991) Induction of somatostatin by kainic acid in pyramidal and granule cells of the rat hippocampus. Neurosci Res 12(4):514–527
Manfridi A, Forloni GL, Vezzani A et al (1991) Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons. Neuroscience 41(1):127–135
Buckmaster PS, Otero-Corchon V, Rubinstein M et al (2002) Heightened seizure severity in somatostatin knockout mice. Epilepsy Res 48(1–2):43–56
Mazarati A, Wasterlain CG (2002) Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci Lett 331(2):123–127
Zafar R, King MA, Carney PR (2012) Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure development. Neurosci Lett 509(2):87–91
Lee KS, Schubert P, Heinemann U (1984) The anticonvulsive action of adenosine: a postsynaptic, dendritic action by a possible endogenous anticonvulsant. Brain Res 321(1):160–164
Dragunow M, Goddard GV, Laverty R (1985) Is adenosine an endogenous anticonvulsant? Epilepsia 26(5):480–487
During MJ, Spencer DD (1992) Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol 32(5):618–624
Fedele DE, Li T, Lan JQ et al (2006) Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200(1):184–190
Huber A, Padrun V, Deglon N et al (2001) Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A 98(13):7611–7616
Guttinger M, Fedele D, Koch P et al (2005) Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 46(8):1162–1169
Li T, Steinbeck JA, Lusardi T et al (2007) Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 130(Pt 5):1276–1288
Guttinger M, Padrun V, Pralong WF et al (2005) Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol 193(1):53–64
Ren G, Li T, Lan JQ et al (2007) Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 208(1):26–37
Theofilas P, Brar S, Stewart KA et al (2011) Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 52(3):589–601
Simonato M, Tongiorgi E, Kokaia M (2006) Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol Sci 27(12):631–638
Yoo YM, Lee CJ, Lee U et al (2006) Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus. Exp Neurol 200(2):407–417
Kanter-Schlifke I, Georgievska B, Kirik D et al (2007) Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 15(6):1106–1113
Rao MS, Hattiangady B, Rai KS et al (2007) Strategies for promoting anti-seizure effects of hippocampal fetal cells grafted into the hippocampus of rats exhibiting chronic temporal lobe epilepsy. Neurobiol Dis 27(2):117–132
Paradiso B, Marconi P, Zucchini S et al (2009) Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 106(17):7191–7196
Paradiso B, Zucchini S, Su T et al (2011) Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52(3):572–578
Bovolenta R, Zucchini S, Paradiso B et al (2010) Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 7:81
Zhang LX, Li XL, Smith MA et al (1997) Lipofectin-facilitated transfer of cholecystokinin gene corrects behavioral abnormalities of rats with audiogenic seizures. Neuroscience 77(1):15–22
Laing JM, Gober MD, Golembewski EK et al (2006) Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 13(5):870–881
McLaughlin J, Roozendaal B, Dumas T et al (2000) Sparing of neuronal function postseizure with gene therapy. Proc Natl Acad Sci U S A 97(23):12804–12809
Yenari MA, Fink SL, Sun GH et al (1998) Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy. Ann Neurol 44(4):584–591
Klugmann M, Symes CW, Leichtlein CB et al (2005) AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci 28(2):347–360
Wykes RC, Heeroma JH, Mantoan L et al (2012) Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med 4(161):161ra152
Shu X, Du S, Chen X et al (2011) Transplantation of neural stem cells overexpressing cardiotrophin-1 inhibits sprouting of hippocampal mossy fiber in a rat model of status epilepticus. Cell Biochem Biophys 61(2):367–370
Krook-Magnuson E, Armstrong C, Oijala M et al (2013) On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun 4:1376
Paz JT, Davidson TJ, Frechette ES et al (2013) Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat Neurosci 16(1):64–70
Sukhotinsky I, Chan AM, Ahmed OJ et al (2013) Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS One 8(4):e62013
LeWitt PA, Rezai AR, Leehey MA et al (2011) AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309–319
Kaplitt MG, Feigin A, Tang C et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369(9579):2097–2105
Racine RJ (1972) Modification of seizure activity by electrical stimulation II Motor seizure. Electroencephalogr Clin Neurophysiol 32(3):281–294
Castillo CG, Mendoza S, Freed WJ, Giordano M (2006) Intranigral transplants of immortalized GABAergic cells decrease the expression of kainic acid-induced seizures in the rat. Behav Brain Res 171:109–115
Sørensen AT, Kanter-Schlifke I, Lin EJ, During MJ, Kokaia M (2008) Activity-dependent volume transmission by transgene NPY attenuates glutamate release and LTP in the subiculum. Mol Cell Neurosci 39:229–37
Li T, Ren G, Kaplan DL, Boison D (2009) Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res 84:238–41
Seki T, Matsubayashi H, Amano T, Kitada K, Serikawa T, Sasa M, Sakai N (2004) Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats. Neurochem Int 45:171–8
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lin, EJ.D., During, M.J. (2015). Gene Therapy for Epilepsies. In: Bo, X., Verhaagen, J. (eds) Gene Delivery and Therapy for Neurological Disorders. Neuromethods, vol 98. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2306-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2306-9_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2305-2
Online ISBN: 978-1-4939-2306-9
eBook Packages: Springer Protocols